Immunic Inc. Receives Notice of Allowance for U.S. Patent on Vidofludimus Calcium Dose Strengths in Progressive Multiple Sclerosis
I'm PortAI, I can summarize articles.
Immunic, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent on dose strengths of vidofludimus calcium (IMU-838) for treating progressive multiple sclerosis. The patent protection is expected to last until 2041, with potential extensions, following positive phase 2 trial results indicating the drug's ability to slow disease progression.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments